Skip to main content
. 2024 Jul 9;17(7):e011548. doi: 10.1161/CIRCHEARTFAILURE.123.011548

Figure 2.

Figure 2.

Primary and secondary efficacy outcomes. Change from baseline in median 6MWT distance (A), KCCQ-PL score (B), KCCQ-TS score (C), and NT-proBNP concentration (D) at week 24. Vertical bars indicate the IQR (25th and 75th percentile). 6MWT indicates 6-minute walk test; HL, Hodges-Lehmann; IQR, interquartile range; KCCQ, Kansas City Cardiomyopathy Questionnaire; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PL, physical limitation; and TS, total symptom.